Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Accounts Payables (2019 - 2026)

Enliven Therapeutics has reported Accounts Payables over the past 8 years, most recently at $1.6 million for Q1 2026.

  • Quarterly results put Accounts Payables at $1.6 million for Q1 2026, up 4.99% from a year ago — trailing twelve months through Mar 2026 was $1.6 million (up 4.99% YoY), and the annual figure for FY2025 was $2.2 million, up 60.88%.
  • Accounts Payables reached $1.6 million in Q1 2026 per ELVN's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.9 million in Q1 2023 and bottomed at $532000.0 in Q4 2023.
  • Median Accounts Payables over the past 5 years was $1.6 million (2025), compared with a mean of $2.0 million.
  • Peak annual rise in Accounts Payables hit 211.04% in 2023, while the deepest fall reached 84.53% in 2023.
  • Over 5 years, Accounts Payables stood at $3.4 million in 2022, then tumbled by 84.53% to $532000.0 in 2023, then skyrocketed by 152.26% to $1.3 million in 2024, then skyrocketed by 60.88% to $2.2 million in 2025, then decreased by 24.04% to $1.6 million in 2026.
  • Business Quant data shows Accounts Payables for ELVN at $1.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.4 million in Q3 2025.